HER2 status and disparities in luminal breast cancers

Article English OPEN
Holowatyj, Andreana N.; Ruterbusch, Julie J.; Ratnam, Manohar; Gorski, David H.; Cote, Michele L.;

Abstract National Comprehensive Care Network guidelines for adjuvant treatment of invasive breast cancer are based on HER2 and hormone receptor (HR) status, where HR+ disease encompasses all estrogen receptor (ER)+ and/or progesterone receptor (PR)+ tumors. We sought to... View more
Share - Bookmark